Russia is now a major supplier to Latin America of Covid-19 vaccines, a development that could have long-standing repercussions for shaping the post-pandemic landscape and further denting the region's US reputation.
Although Moscow faces domestic demonstrations and criticism of human rights concerns from the US, France, UK, Canada and other Western countries, those issues have seen little resonance in Latin America, where the recent publication in The Lancet, Britain's leading medical journal, of a favorable peer-reviewed appraisal of the Russian Sputnik V vaccine was widely praised.
Eduardo Valdes, a former diplomat and member of government coalition Frente de Todos, who now serves as chair of the Foreign Affairs Committee in Argentina's Chamber of Deputies, says there's a clear line between vaccine negotiations and external factors.
Turning to Moscow for help
Although traditionally seen as the diplomatic "backyard," of Washington, Latin America is gradually looking to Moscow for assistance in coping with the pandemic. The Sputnik V vaccine has now been approved for use in six countries in the region—Argentina, Bolivia, Mexico, Nicaragua, Paraguay, and Venezuela. Others are considering permission petitions, which, given the global lack of vaccinations, are increasingly urgent.
The case of Colombia is an example: Bogotá, America's nearest regional partner, is now willing to approve Sputnik V as well—a move that shocked many because of the near alignment between some parts of the coalition government and the Republican Party. In the past, right-wing supporters of Centro Democrático, Duque's own faction, have publicly opposed Putin's presence in Latin America.
But when, at the end of January, the nation found itself without vaccinations in hand, Duque seemed to have chosen to put ideology to the side. Colombia declared the day after the release of The Lancet on Sputnik V that it was entered into talks with Russia.
Less than three months ago, in uncertain conditions, Bogotá had dismissed two Russian officials. But the deportation "did not influence the negotiations to bring here the vaccine," Leonid Sboiko, First Secretary of the Russian Embassy in Bogotá, told CNN. The Colombian Ministry of Health has refused to comment on the state of the talks.
If anything, the vaccine deal could be a step toward smoothing things over. "Both countries want to turn the page. It was regrettable, but we want to move on," Sboiko said, adding, "Cooperating on the vaccines is the most pressing issue right now, and is going to positively influence [Colombia and Russia's] bilateral relationships."
Colombia will begin vaccinations this week, after receiving 50,000 doses as first shipment from Pfizer.
Ease of doing business
In the region, the need to secure more vaccines is desperately felt. Latin American nations have been among the most impacted by the pandemic in the world, however, with few exceptions, large-scale vaccine programs have not yet begun.
According to the University of Oxford, South American countries have on average dispensed less than two doses of any coronavirus vaccine per 100 people, compared to almost five doses per 100 people in the EU and over 14 doses per 100 people in the US.
According to Danil Bochkov, an international relations expert at the Russian International Affairs Council, Russia's readiness to enter into agreements has been crucial in spreading the vaccine across Latin America so far.
"It is always easier to deal with the state than with a private company, which has to hedge possible risks fearing huge losses. State-owned companies are easier to negotiate with, especially when they are pursuing political goals," Bochkov told
Argentina has so far purchased up to 25 million doses of the Sputnik vaccine and dispensed over 600,000 doses. Meanwhile, it is still waiting to dispense the first Pfizer vaccine.
In a statement to CNN, Pfizer said the company remains committed to working with the Argentinian government but refused to comment on the status of confidential negotiations.
Regional neighbors Peru and Brazil have also cited issues in negotiations with Pfizer, allegedly because of some of the liability clauses it requested, and ultimately turned to other vaccines — Chinese-made Sinopharm in Peru, and Coronavac and AstraZeneca in Brazil.
Apart from ease of negotiations, two more factors have worked to advantage the spread of Sputnik V through Latin America, according to analysts and lawmakers involved in vaccine purchases in Argentina and Bolivia: Sputnik V is cheap, and relatively easy to store.
Even before the negotiations start, the RDIF lists Sputnik V's price at approximately $10 per doses — roughly half the price of the Pfizer vaccine, which costs $19.50 per dose. Latin American economies have been badly hit by the pandemic, and any possible saving is more than welcome by administrators and politicians.
The Russian vaccine can also be stored at a temperature of 2 to 8°C (35 to 45°F) and does not require the ultra-freezing temperature the Pfizer vaccine is stored at. Most of Latin America lacks the infrastructure to maintain ultra-freezing temperatures, especially in rural regions with limited road access.
Other privately made vaccines, like those made by AstraZeneca and Moderna, are yet to arrive in large quantities in Latin America, while countries like Brazil, Chile and Mexico have invested in Chinese-made vaccines.
Around the world, 26 countries have approved the Sputnik V vaccine.
What Russia stands to gain
In Buenos Aires, Bogota and La Paz, former diplomats and analysts say Russian President Vladimir Putin could now reap benefits from the spread of the vaccine, potentially using it as a global business card to begin new and more forgiving relationships.
"Russia made a big bet on the vaccine: in the last few years, Russia has re-discovered Latin America, not for ideology but because if your goal is to question the norms and values of the liberal international order, Latin America is a region particularly sensitive to that goal," Serbin said.
Both Russia and China are looking to improve their reputations after years of confrontation with the US and the EU, and the role of vaccine provider for the developing world is a perfect opportunity for a positive PR campaign. As Bochkov puts is, "Russia has mastered the Sputnik V as a diplomatic instrument so far."
Commercially, selling millions of vaccine doses also means turning multi-million dollar profits — something of primary importance for the Russian economy, which has been hit by Western sanctions in recent times.
In contrast, the West's handling of vaccine distribution has often seemed inward-looking. In January, Britain and the EU squabbled over vaccine distribution, while the White House bulked up purchases of vaccines to a total of more than 7 potential doses available for every American, according to data collected by Duke University.
"The difference is that the United States are working to get vaccines mostly to vaccinate US citizens. Others like Russia and China are looking to stretch relationships where they can," Pablo Solon, a former Bolivian ambassador to the United Nations.
A missed opportunity for the West?
Western powers could have seized the political — and even moral — advantage, says Amadeo Gandolfo, an Argentinian scholar in political communication at Berlin's Humboldt University. He argues that Western countries missed a key opportunity to claim a moral victory when they allowed companies to patent their vaccines.
"Faced with the absolute necessity for the whole world to obtain the vaccine, leaving it in the hands of the pharmaceutical companies and not allowing a liberalization of the formula, I think it is something that pushed some sectors of Latin America away," he told .
Now, as with any new patented product, the privately developed vaccines are protected by property right and cannot be replicated by other companies or countries. So while private companies like Pfizer and AstraZeneca are struggling to meet committed orders, other laboratories cannot step in to produce the same vaccines and increase supplies.
Many Western countries have instead invested in the Covax mechanism, a framework promoted by the World Health Organization to purchase vaccines in bulk and secure deliveries to developing countries that cannot afford to purchase them on their own.
But while Covax promises to inoculate up to 20% of the developing world and says it will prioritize four Latin American countries including Bolivia and Colombia for early access, it has yet to deliver a single dose.
Whether vaccination efforts would be more equal if Western pharmaceutical companies were not allowed to patent and commercialize the vaccines has been discussed since the beginning of the pandemic. An effort by South Africa and India urging the World Trade Organization to suspend intellectual property rights related to Covid-19 has so far proved unsuccessful.
This will cost Western governments dearly in post-pandemic geopolitics, argues Solon, the Bolivian diplomat. "The world has been multipolar for some time," he told CNN. "But within this multipolar world Russia and China are advancing fast. This vaccine situation is only strengthening the trend."